OPTINOSE INC. - COMMON STOCK

Optinose to Present at the Needham Virtual Healthcare Conference

04 апр 2024 16:01:00 Источник Nasdaq GlobeNewswire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

15 мар 2024 15:34:50 Источник Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

07 мар 2024 07:00:43 Источник Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

29 фев 2024 16:40:00 Источник Nasdaq GlobeNewswire

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

18 янв 2024 12:00:00 Источник Nasdaq GlobeNewswire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

06 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

22 ноя 2023 09:00:00 Источник Nasdaq GlobeNewswire

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

09 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

27 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Optinose to Present at the 2023 Cantor Global Healthcare Conference

22 сен 2023 09:01:00 Источник Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

10 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

27 июл 2023 07:00:01 Источник Nasdaq GlobeNewswire

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 июн 2023 16:08:00 Источник Nasdaq GlobeNewswire

Optinose to Present at the Jefferies Healthcare Conference

02 июн 2023 13:00:00 Источник Nasdaq GlobeNewswire

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

11 май 2023 07:00:18 Источник Nasdaq GlobeNewswire

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

04 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

01 май 2023 16:30:00 Источник Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

12 апр 2023 16:00:00 Источник Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

07 мар 2023 07:00:56 Источник Nasdaq GlobeNewswire